{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060026","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.265913+00:00","generated_at":"2026-06-01T23:25:35.084401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated","bullets":["Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.","Cash and equivalents $4.7M; operating cash burn $4.9M, down ~40% from prior quarter.","Total test volume 806 (82% billable); primary care orders up 33% QoQ.","Strategic sale process initiated with multiple potential acquirers in discussions.","FDA-authorized kidneyintelX.dkd launched April 2024; Medicare coverage draft issued."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060026","json":"https://secwatch.observer/filing/0000950170-24-060026.json","markdown":"https://secwatch.observer/filing/0000950170-24-060026.md","text":"https://secwatch.observer/filing/0000950170-24-060026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/0000950170-24-060026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/rnlx-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:25:35.084401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54890c6046168e83be11ab5e575867f7e6b9a7d8","claim":"Renalytix plc reported the fiscal third quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss was $7.7 million.","evidence_excerpt":"During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/0000950170-24-060026-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"Net loss was $7.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}